Note:  This web page has links to many articles, fact sheets, and other materials arising from the 2014 International AIDS Conference (IAC), held during July 2014 in Melbourne, Australia.

The materials have been grouped into topic areas to help you scan and quickly find materials of particular interest to you.  The topic areas appear in the order listed below.  Please note that some articles appear in more than one topic category:

• Conference Overview and Highlights
• The Global Epidemic
• Affected Population Groups and Health Disparities
• HIV Prevention, Transmission, and Testing
• HIV Treatment
• Research Toward an HIV Cure
• Living with HIV
• Hepatitis C Virus (HCV) Infection

Conference Overview and Highlights

AIDS 2014 – This is the official website for the 2014 IAC.  It includes the conference program-at-a-glance; “daily delivery” archives of conference news; and video interviews. Of particular interest are the site’s rapporteur summaries – detailed daily reports of major findings and discussions – for each of the  main tracks of AIDS 2014:

• Track A: Basic and Translational Research
• Track B: Clinical Research
• Track C: Epidemiology and Prevention
• Track D: Social and Political Research, Law, Policy, and Human Rights
• Track E: Implementation Research, Economics, Systems, and Synergies with other Health and Development Sectors
• Community Program
• Leadership & Accountability Program
• Global Village
• Youth Program

General Overview Articles:

• Really Rapid Review — AIDS 2014, Melbourne (Journal Watch)
• AIDS 2014: Videos, Webcasts, and Tweets, Oh My!  (BETABlog)
• AIDS 2014 Conference Highlights (video) (HIVandhepatitis)
• Revisiting Memorable Moments From AIDS 2014.  (TheBodyPro)
• HIV Prevention Tops the News at AIDS 2014.   (BETAblog)
• AIDS 2014 Recap: Meeting the Needs of Transgender Women.  (BETAblog)
• AIDS 2014: Untangling HIV and Aging.  (BETAblog)
• Hepatitis C Now a Theme at International AIDS Conference.  (BETAblog)
• Bill Clinton addresses International AIDS Conference delegates.  (ScienceSpeaksBlog)
• Paul Semugoma receives human rights award at Monday plenary session.  (ScienceSpeaksBlog)
• AIDS 2014 to Focus on Scaling Up What Works.  (TheBodyPro)
• AIDS 2014 Conference Opens with Tributes and Treatment Targets. (BETABlog)
• AIDS 2014 opening ceremony honours Flight MH17 dead with drive to end AIDS by 2030.  (AIDSmap)
• AIDS 2014 Snapshots: U.S. in the Lens, Sex Workers Refuse to Be Unseen, and Everyone’s Got a Point of View.  (TheBodyPro)
• Beyond Blame, Key Populations and PrEP: An AIDS 2014 Overview.  (Poz)
• AIDS Crisis, or Funding Crisis: Call for Resources Comes From All Corners of AIDS 2014.  (TheBodyPro)
• AIDS 2014 Mobilization: Activists Demand More HIV Funding, End Stigma (video) (HIVandhepatitis)
• From Pragmatic to Profound, It’s All Powerful: Snapshots as AIDS 2014 Begins to Close.  (TheBodyPro)
• Of guidelines, targets and resources: the documents that defined the 2014 International AIDS Conference.  (AIDSmap)

Blog.AIDS.gov: Highlights and Conversations from 2014 IAC:

• In Case You Missed it! AIDS 2014 Roundup
• Stepping Up the Pace in America’s Response to AIDS
• NIH’s Dr. Carl Dieffenbach Shares Final Thoughts from AIDS 2014
• Conversations from AIDS 2014: Practitioner Bisola Ojikutu
• NIH’s Dr. Gina Brown Reflects On HIV Among Women and Girls – Highlights From AIDS 2014
• NIH’s Dr. Carl Dieffenbach Shares Highlights from Thursday at AIDS 2014
• Harnessing the Potential of Social Media in HIV Prevention – Voices From AIDS 2014
• NIH’s Dr. Carl Dieffenbach Shares Highlights from Wednesday at AIDS 2014
• Conversations from AIDS 2014: Mary Mahy, UNAIDS
• If You Film It, Will They Watch?
• NIH’s Dr. Carl Dieffenbach Shares a Highlight from Day 3 of AIDS 2014 on Making Better, Smarter Investments to Achieve AIDS-Free Generation
• Conversations from AIDS 2014: Ron Valdiserri and Phill Wilson
• AIDS 2014 Day 3: CDC’s Laura Kann on Adolescents and HIV-Related Risk Behavior
• NIH’s Dr. Carl Dieffenbach Shares Science Highlight from Second Day of AIDS 2014
• Ambassador Birx Shares Highlights from AIDS 2014 and Introduces PEPFAR Dashboards
• NIH’s Dr. Carl Dieffenbach Looks Ahead to Key Topics to Be Explored At AIDS 2014
• Dr. Fauci Reflects on HIV Colleagues Lost in Flight MH-17

The Global Epidemic
(including prevention and treatment goals, funding, and access to care)

• A new target for HIV treatment from UNAIDS.  (ScienceSpeaksBlog)
• ART demand up to 16.8 million by 2016. (AIDSmap)
• UNAIDS Gap Report Finds Half of HIV+ People Worldwide Are Unaware of Status.  (HIVandhepatitis)
• HIV Treatment Demand in Poorer Nations to Keep Rising.  (Poz)
• Of guidelines, targets and resources: the documents that defined the 2014 International AIDS Conference.  (AIDSmap)
  It’s Time to ‘Step Up the Pace’ Against Global HIV.  (Poz)
• What is needed to ‘step up the pace’ on HIV prevention and treatment?  (AIDSmap)
• Financing the new global HIV treatment vision – advocacy and economics.  (ScienceSpeaksBlog)
• Law and Policy Must Be Part of the Solution for AIDS (video).  (HIVandhepatitis)
• No One Left Behind in Response to HIV/AIDS (video). (HIVandhepatitis)
• Undetectable viral load an opportunity for all by 2020 is activists’ call for action.  (ScienceSpeaksBlog)
• “What good are interventions if we live like we have a gun to our heads?”  (ScienceSpeaksBlog)
• Criminalization Fuels HIV/AIDS Epidemic (video). (HIVandhepatitis)
• Police Can Play a Role in Reducing HIV (video).  (HIVandhepatitis)
• Melbourne Declaration – Nobody Left Behind  (HIVandhepatitis)
• A look at AIDS 2014: Stigma and discrimination pose barriers to accessing health services.  (ScienceSpeaksBlog)
• When HIV Research and Data Collection Is at Odds with “Do No Harm.” (healthpolicyproject)
• Pediatric treatment planning, action call at last plenary. (ScienceSpeaksBlog)
• Human Rights Violations Create HIV Risk Environment in the U.S. South.  (TheBodyPro)
• HIV Trends in San Francisco and London: An AIDS 2014 Q&A.  (BETABlog)
• Nearly half of young gay men in Bangkok not using condoms consistently acquire HIV within five years of starting sex.   (AIDSmap)
• Peer programs engage injection drug users in Kenya and Tanzania. (ScienceSpeaksBlog)
• Treatment as prevention may not work in Africa without couples counselling.  (AIDSmap)
• Médecins Sans Frontières releases viral load and antiretroviral drug pricing reports.  (ScienceSpeaksBlog)
• Adolescent deaths from AIDS rising, especially among boys.  (AIDSmap)
• European Economic Downturn Tied to HIV Uptick in Drug Users.  (Poz)
• Recession and income inequality have fuelled HIV infections in European drug users.  (AIDSmap)

Affected Population Groups and Health Disparities

Children and Youth:

• Adolescent deaths from AIDS rising, especially among boys.  (AIDSmap)
• Liver Markers Worse in Youth With Than Without HIV and Climb Over Time. (NATAP)
• Young Drug Users at Especially High Risk of HIV and Hep C.  (Poz)
• Strong performance on HIV drugs for mothers doesn’t guarantee optimal care for infants, survey shows. (AIDSmap)
• Pediatric treatment lag demands planning, action, final plenary speaker says. (ScienceSpeaksBlog)
• Young people with HIV respond well to human papillomavirus vaccine.  (AIDSmap)

Gay, Bisexual, and Other Men Who Have Sex with Men:

• Gay Men, MSM and Transgender Pre-Conference Kicks Off in Melbourne.  (ScienceSpeaksBlog)
• Men who have sex with men and transgender women have risks and resilience.  (ScienceSpeaksBlog)
• MSMGF, Johns Hopkins University Unveil New Gay Men’s Health Curriculum for Healthcare Providers.  (TheBodyPro)
• Globally, 1 in 12 MSM have been arrested for same-sex behaviour.  (AIDSmap)
• Criminalizing Homosexuality Hampers HIV Prevention & Care. (Poz)
• HIV is increasing in gay men in London because of lack of testing, comparative study finds.  (AIDSmap)
• HIV Trends in San Francisco and London: An AIDS 2014 Q&A.  (BETABlog)
• Testing, Safer Sex Reduces HIV in SF Gays Compared With London.  (Poz)
• Gay men interested in taking PrEP already report high-risk behaviour.  (AIDSmap)
• 100% Efficacy for Gays Who Adhered in PrEP Study; Most Didn’t.  (Poz)
• The more drugs gay men have taken, the more likely they are to have unprotected sex. (AIDSmap)
• The More the Party Drugs, the Fewer the Condoms Among Gay Men.  (Poz)
• Most gay men who don’t use condoms are mindful of HIV and attempt to reduce their risk.  (AIDSmap)
• Condoms Aren’t the Only Way That Gay Men Reduce HIV Risk. (Poz)
• Communicating Out of Isolation: HIV and Harnessing Communication Technology Among Gay Men, Men Who Have Sex with Men, and Trans Persons. (healthpolicyproject)
• Anal lesions often resolve without treatment in HIV-positive gay men.  (AIDSmap)
• Precancerous Rectal Lesions in Gays With HIV May Clear on Their Own.  (Poz)
• Nearly half of young gay men in Bangkok not using condoms consistently acquire HIV within five years of starting sex.   (AIDSmap)

Older Persons and HIV:

• AIDS 2014: Untangling HIV and Aging.  (BETAblog)

Sex Workers:

• The Lancet launches special issue on HIV and sex work.  (ScienceSpeaksBlog)
• The Lancet Says Decriminalizing Sex Work Could Significantly Reduce HIV Infections.  (TheBodyPro)
• Criminalization of Sex Work Increases Vulnerability to HIV.  (HIVandhepatitis)

Substance Users:

• Recession and income inequality have fuelled HIV infections in European drug users.  (AIDSmap)
• European Economic Downturn Tied to HIV Uptick in Drug Users.  (Poz)
• Harm reduction and drug policy – no one left behind.  (ScienceSpeaksBlog)
• Harm reduction funding meeting only 7% of global need.  (AIDSmap)
• Young Drug Users at Especially High Risk of HIV and Hep C.  (Poz)
• Interferon-free hepatitis C treatment works for people on methadone or buprenorphine.  (AIDSmap)

Transgender Persons:

• AIDS 2014 Recap: Meeting the Needs of Transgender Women.  (BETAblog)
• Addressing the Sexual Health and HIV Prevention Needs of Same-Sex Attracted Transgender Men.  (TheBodyPro)
• Communicating Out of Isolation: HIV and Harnessing Communication Technology Among Gay Men, Men Who Have Sex with Men, and Trans Persons. (healthpolicyproject)
• Gay Men, MSM and Transgender Pre-Conference Kicks Off in Melbourne.  (ScienceSpeaksBlog)
• Men who have sex with men and transgender women have risks and resilience.  (ScienceSpeaksBlog)

Women:

• New analysis suggests increased risk of HIV infection for women using contraceptive injections.  (AIDSmap)
• Positively Fabulous Aims to Change HIV+ Women’s Lives (video).  (HIVandhepatitis)
• AIDS 2014: Adult Male Circumcision Also Protects Women from HIV Infection.  (HIVandhepatitis)

HIV Prevention, Transmission, and Testing

HIV Treatment as Prevention:

• Treatment as prevention may not work in Africa without couples counselling.  (AIDSmap)
• Could HIV treatment mean safer sex?  (AIDSmap)

Pre-Exposure Prophylaxis (PrEP):

• PrEP is a beginning with new prevention technologies in the works.  (ScienceSpeaksBlog)
• How will people use PrEP? iPrEx users talk condoms, pills, anxiety and relief.  (AIDSmap)
• Gay men interested in taking PrEP already report high-risk behaviour.  (AIDSmap)
• Overall PrEP effectiveness in iPrEx OLE study 50%, but 100% in those taking four or more doses a week.  (AIDSmap)
• Zero HIV Infections When PrEP Is Taken 4 or More Times a Week.  (TheBodyPro)
• 100% Efficacy for Gays Who Adhered in PrEP Study; Most Didn’t.  (Poz)
• PrEP Works Despite Missed Doses, Although Daily Use Is Advised.  (BETABlog)
• Good adherence seen in study of intermittent PrEP.  (AIDSmap)
• Early Data Show Good Adherence to Intermittent PrEP by MSM in French Trial.  (NATAP)
• HIV Preventive Tx Appears Safe for Fetus.  (MedPageToday – free registration may be required to access).
• Study on Intermittent Dosing of PrEP Suggests High Adherence.  (Poz)

Post-Exposure Prophylaxis (PEP):

• Meta-analysis: only half the people who start PEP complete the course.  (AIDSmap)

HIV Testing:

• UNAIDS Gap Report Finds Half of HIV+ People Worldwide Are Unaware of Status.  (HIVandhepatitis)
• HIV is increasing in gay men in London because of lack of testing, comparative study finds.  (AIDSmap)
• Testing, Safer Sex Reduces HIV in SF Gays Compared With London.  (Poz)
• Home-testing acceptable in ‘treat everyone’ trial: treatment takes longer to accept.  (AIDSmap)
• What needs to be done to make HIV self-testing a reality? (AIDSmap)

Other HIV Transmission and Prevention News:

• HIV Prevention Tops the News at AIDS 2014.   (BETAblog)
• Tackling moral judgments about sex and sexuality is vital for HIV prevention. (AIDSmap)
• When Science Meets HIV Prevention, Pleasure Cannot Be Left Behind.  (TheBodyPro)
• A (Cyber) Space for Community for HIV prevention. (healthpolicyproject)
• More data suggest increased risk of HIV infection for women using contraceptive injections.  (AIDSmap)
• Addressing the Sexual Health and HIV Prevention Needs of Same-Sex Attracted Transgender Men.  (TheBodyPro)
• Most gay men who don’t use condoms are mindful of HIV and attempt to reduce their risk.  (AIDSmap)
• Condoms Aren’t the Only Way That Gay Men Reduce HIV Risk. (Poz)
• Those in Poorer Nations Don’t Drop Condoms When on HIV Meds.  (Poz)
• The more drugs gay men have taken, the more likely they are to have unprotected sex. (AIDSmap)
• The More the Party Drugs, the Fewer the Condoms Among Gay Men.  (Poz)
• Sustainable VMMC [circumcision] programs: They Didn’t Mean To! Article.  (healthpolicyproject)
• Circumcision Reduces Syphilis Rates in Both Men and Women.  (Poz)
• AIDS 2014: Adult Male Circumcision Also Protects Women from HIV Infection.  (HIVandhepatitis)
• Significantly less syphilis in female partners of circumcised men.  (AIDSmap)
• Criminalizing Homosexuality Hampers HIV Prevention & Care. (Poz)
• Harm reduction and drug policy – no one left behind.  (ScienceSpeaksBlog)
• Harm reduction funding meeting only 7% of global need.  (AIDSmap)
• Powerful HIV Antibodies May Require Assist from Second Antibody to Develop. (NIAID)

 HIV Treatment

Note:  For articles about HIV treatment as prevention, please see the “HIV Prevention, Transmission, and Testing” section above.

Global Treatment Targets and Demand:

• A new target for HIV treatment from UNAIDS.  (ScienceSpeaksBlog)
• ART demand up to 16.8 million by 2016. (AIDSmap)
• It’s Time to ‘Step Up the Pace’ Against Global HIV.  (Poz)
• What is needed to ‘step up the pace’ on HIV prevention and treatment?  (AIDSmap)
• Financing the new global HIV treatment vision – advocacy and economics.  (ScienceSpeaksBlog)
• Undetectable viral load an opportunity for all by 2020 is activists’ call for action.  (ScienceSpeaksBlog)

Starting and Changing HIV Treatment (including concerns about HIV drug resistance):

• Antiretroviral treatment update kicks off final plenary session. (ScienceSpeaksBlog)
• TAG Releases 2014 HIV, Hepatitis C, and Tuberculosis Pipeline Report.  (HIVandhepatitis)
• Successful ART Started Under Age 6 Months More Likely to Yield Negative Antibody Test.  (NATAP)
• Switching From First-Line ART When Suppressed Boosts Failure Chance.  (NATAP)
• Switching from first-line ART with suppressed viral load linked to treatment failure. (AIDSmap)
• Dolutegravir demonstrates good efficacy despite resistance.  (AIDSmap)
• DTG-Based Regimens Are Active in INI-Naive Patients With a History of NRTI Resistance.  (NATAP)
• Effect of viral suppression below 20 copies of HIV-RNA /mL of plasma on virological outcome of treated HIV- infected patients.  (NATAP)
• Failure Risk Similar With 20 to 50 Copies and Always Under 20 Copies.  (NATAP)
• Good Response and Resistance Record in Naive and Experienced Starting Dolutegravir.  (NATAP)

Studies Comparing Different HIV Treatment Regimens:

• Maraviroc fails to match tenofovir/emtricitabine for first-line HIV treatment.  (AIDSmap)
• Once-Daily Maraviroc Inferior to TDF/FTC in First-Line Regimens With Darunavir.  (NATAP)
• Maraviroc (MVC) Once Daily With Darunavir/Ritonavir(DRV/r) Compared to Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: 48-Week Results From MODERN (Study A4001095).  (NATAP)
• Selzentry (Maraviroc) Fails to Best Truvada as First-Line Therapy. (Poz)
• Virologic Failure Predictors in SECOND-LINE Trial of Raltegravir vs NRTIs. (NATAP)

HIV Drug Pricing and Access:

• The Medicines Patent Pool (MPP) Broadens Collaboration With Gilead Sciences: Signs License for Phase III Medicine Tenofovir Alafenamide (TAF).  (TheBodyPro)

Research Toward an HIV Cure

• World Without AIDS: Update on HIV Cure and Vaccine Research.  (TheBodyPro)
• AIDS 2014: Researchers discuss progress towards an HIV cure.  (AIDSmap)
• HIV Cure Research: Where We Are, Where We Are Headed. (NIAID)
• At AIDS 2014, Dr. Anthony S. Fauci Discusses Key Challenges in HIV Scientific Discovery: Cure, Vaccine. (NIAID)
• Novel techniques probed in cure research.  (AIDSmap)
• Setbacks and Progress in the Search for an HIV Cure. (BETAblog)
• cART in First Days of Life Limits Viral Reservoir Size in 4 Canadian Children.  (NATAP)
• 2 Australian Men “Cleared” of HIV After Bone Marrow Transplants.  (TheBodyPro)
• The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays. (NATAP)
• Drug Spurs Latently Infected Cells But Doesn’t Taper HIV Reservoir.  (Poz)
• Romidepsin activates latent HIV, but does not decrease viral reservoir.  (AIDSmap)
• NIH-Supported Scientists Demonstrate Very Early Formation of SIV Reservoir. (NIAID)

Living with HIV
(includes TB and other health conditions in HIV-infected persons)

Note: For articles about hepatitis C infection, please see the “Hepatitis C” section below.

Tuberculosis:

• TB HIV goals closer to rhetoric than reality, report released here shows.  (ScienceSpeaksBlog)
• HIV and tuberculosis are one disease in Southern Africa.  (ScienceSpeaksBlog)
• HIV and tuberculosis co-infection – no one left behind.  (ScienceSpeaksBlog)
• GeneXpert with clinic-based care reduced time to treatment for MDR TB patients in Khayelitsha, South Africa.  (ScienceSpeaksBlog)
• Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test.  (AIDSmap)
• Novel TB regimen could reduce treatment duration.  (AIDSmap)
• PaMZ TB drug regimen: Cheaper, simpler, safer, and with effectiveness “significantly greater” than standard regimen, researchers say.  (ScienceSpeaksBlog)
• Novel PaMZ Tuberculosis Regimen Could Reduce Treatment Duration.  (HIVandhepatitis)
• TAG Releases 2014 HIV, Hepatitis C, and Tuberculosis Pipeline Report.  (HIVandhepatitis)

Other Health Conditions:

• Efavirenz use not linked to neurocognitive impairment.  (AIDSmap)
• No Link Between Efavirenz and Neurocognitive Impairment in Italian Study.  (BETAblog)
• Anal lesions often resolve without treatment in HIV-positive gay men.  (AIDSmap)
• Precancerous Rectal Lesions in Gays With HIV May Clear on Their Own.  (Poz)
• Higher One-Year Risk of CVD or Diabetes Per BMI Unit Gained on ART.  (NATAP)
• Weight gain on ART may raise risk of heart disease and diabetes.  (AIDSmap)
• Quadrivalent HPV Vaccine Elicits Antibody and Cell Responses in HIV+ Teens, Young Adults.  (NATAP)
• Young people with HIV respond well to human papillomavirus vaccine. (AIDSmap)
• Inflammation/Activation Markers Drop With ATV, DRV, RAL, But Not Completely – ACTG Study.  (NATAP)
• Tesamorelin May Help HIV Patients Shed Fat.  (MedPageToday – free registration may be required to access).
• COPD Rate 7% in Global HIV Cohort – Half With COPD Never Smoked.  (NATAP)

Hepatitis C Virus (HCV) Infection

The HCV Epidemic:

• Young Drug Users at Especially High Risk of HIV and Hep C.  (Poz)

HCV Treatment:

• TAG Releases 2014 HIV, Hepatitis C, and Tuberculosis Pipeline Report.  (HIVandhepatitis)
• Hepatitis C Now a Theme at International AIDS Conference.  (BETAblog)
• AbbVie 3D regimen cures most genotype 1 HCV in people with HIV and HCV co-infection.  (AIDSmap)
• AbbVie s ‘3D’ Regimen Shows Promise in Those With Hep C & HIV.  (Poz)
• AbbVie’s Hep C Regimen Is Safe with Opioid Replacement Therapy.  (Poz)
• High Response Rates With Triple-DAA Regimen in People With HCV and HIV.  (NATAP)
• SVR12 Rate 97% With 3 DAAs Plus Ribavirin in People on Opioid Replacement.  (NATAP)
• High SVR12 With Sofosbuvir/Ribavirin in HCV/HIV-Coinfected: PHOTON-2.  (NATAP)
• Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection.  (AIDSmap)
• Sovaldi and Ribavirin Cure High Rates of Those With HIV & Hep C.  (Poz)
• Interferon-free hepatitis C treatment works for people on methadone or buprenorphine.  (AIDSmap)
• TURQUOISE-I: Safety and Efficacy of ABT-450/Rombitasvir, Dasabuvir, and Ribavirin in Patients Co-Infected with Hepatitis C and HIV-1.  (NATAP)

HCV Drug Pricing:

• Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug.  (TheBodyPro)